The message Dendreon is sending to doctors is that Provenge and Zytiga can and shoud be used sequentially when treating prostate cancer patients. Data from a Dendreon-run sequencing study of both drugs will be ready next year. The company also announced Friday that it will run a similar sequencing study with Dendreon and Medivation's (MDVN - Get Report) Xtandi, which roared out of the launch gate earlier this week.
Both Zytiga and Xtandi are formidable competitors if doctors decide that either drug is a suitable replacement for Provenge.
Dendreon reported a net loss of $154.9 million in the third quarter 2012 compared to a net loss of $147.1 million in the year-ago quarter. This quarter's net loss included $81 million in charges associated with the previously announced restructuring aimed at reducing the company's overhead and expenses.
-- Reported by Adam Feuerstein in Boston.Follow @AdamFeuerstein